MedTrace Logo

Haemocomplettan® P During Aortic Replacement

NCT00701142 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-09-20

No results posted yet for this study

Summary

The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.

Conditions

  • Aortic Aneurysm

Interventions

BIOLOGICAL

Haemocomplettan® P

Single intravenous infusion

BIOLOGICAL

Saline solution

Single intravenous infusion

Sponsors & Collaborators

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • Niels Rahe-Meyer, Dr. Dr. · Abteilung Anästhesiologie, Carl-Neuberg-Strasse 1 / K5, 30177 Hannover

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701142 on ClinicalTrials.gov